Michael J. Fox Foundation
Toronto, ON M5H 2V1
CEO: Todd Sherer
Board Chair: Jeff Keefer
Charitable Reg. #: 83230 9892 RR0001
Social Results Reporting
Grade: C+The grade is based on the charity's public reporting of the work it does and the results it achieves.
Program Cost Coverage
Full-time staff #0
Avg. Compensation $0
Top 10 Staff Salary Range
|$300k - $350k||0|
|$250k - $300k||0|
|$200k - $250k||0|
|$160k - $200k||0|
|$120k - $160k||0|
|$80k - $120k||0|
|$40k - $80k||0|
About Michael J. Fox Foundation:
Established in 2009, the Michael J. Fox Foundation for Parkinson's Research Canada (MJFF) funds research that looks for improved treatments and a possible cure for Parkinson's disease. The Michael J. Fox Foundation for Parkinson's Research USA controls MJFF operations and distributes research grants on MJFF's behalf. The foundations share a common website and report on their granting activities, grantee outputs and grantee outcomes collectively. Ci could not determine where MJFF directs Canadian donations with respect to the research successes and funded researchers reported on the main MJFF website.
The Michael J. Fox Foundation for Parkinson's Research's leadership team consists of businesspeople and PhD neuroscientists. By combining science with business, the Foundation believes that its granting activities will lead to a cure for Parkinson's disease as quickly as possible.
The drug development process follows three major stages: basic research, translational research, and clinical research. In basic research, researchers look at underlying biological processes and their importance in cells at the test tube level. Translational research looks at the discoveries from basic research in the context of diseases such as Parkinson's. This leads to new drug ideas that then enter clinical research. At this stage, researchers test potential drugs on humans. Most drug ideas fail in the translational to clinical transition, which is where MJFF comes into play. Most of MJFF's funding focuses on translational and clinical research. By supporting the stages where drug development traditionally stops, MJFF believes that its strategic investments are speeding up the timeline for discovering a cure.
The Michael J. Fox Foundation for Parkinson's Research website outlines four research priorities: Altering Disease, Defining PD, Untreated Symptoms and Tools. Altering disease is the Foundation's top priority and focuses on developing a drug that restores damaged nerve cells in Parkinson's patients. Defining PD research focuses on finding biomarkers that will allow researchers to predict the risk and progression of Parkinson's disease in people, and evaluate whether current treatments are working in Parkinson's patients. Untreated Symptoms research addresses currently untreated symptoms of Parkinson's disease and the side effects of current drugs. With the Tools priority area, MJFF creates and distributes research tools to researchers so that they can focus on actually curing Parkinson's disease.
Michael J. Fox Foundation is a medium-sized charity with total donations of $3.4m in F2015, $2.1m of which was received from The Michael J. Fox Foundation USA. Administrative costs are 1% of donations. MJFF does not report any fundraising costs in its audited financial statements or T3010 CRA filings.
MJFF holds $1.7m in funding reserves, which consists only of cash. Funding reserves can cover only 73% of annual granting activities, indicating a funding need.
MJFF reports no compensation information in its most recent F2014 T3010 CRA filing. The charity's F2015 T3010 was not available when this report was created.
This charity report is an update that is currently being reviewed by Michael J. Fox Foundation. Changes and edits may be forthcoming.
Updated on July 18, 2016 by Katie Khodawandi.
Financial RatiosFiscal year ending December
|Administrative costs as % of revenues||0.5%||0.8%||1.0%|
|Fundraising costs as % of donations||0.0%||0.0%||0.0%|
|Program cost coverage (%)||73.3%||49.6%||27.9%|
Summary Financial StatementsAll figures in $s
|Cash flow from operations||1,142,948||312,704||138,913|